Recent advances in idiopathic pulmonary fibrosis

Sanghoon Park, Eun Joo Lee

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalTuberculosis and Respiratory Diseases
Volume74
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Idiopathic Pulmonary Fibrosis
Clinical Trials
Acetylcysteine
Warfarin
Licensure
Inflammation
Growth

Keywords

  • Clinical trial
  • Etiology
  • Idiopathic pulmonary fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Recent advances in idiopathic pulmonary fibrosis. / Park, Sanghoon; Lee, Eun Joo.

In: Tuberculosis and Respiratory Diseases, Vol. 74, No. 1, 01.01.2013, p. 1-6.

Research output: Contribution to journalReview article

@article{faa34a008629445a98ca31371a6ef963,
title = "Recent advances in idiopathic pulmonary fibrosis",
abstract = "The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright",
keywords = "Clinical trial, Etiology, Idiopathic pulmonary fibrosis",
author = "Sanghoon Park and Lee, {Eun Joo}",
year = "2013",
month = "1",
day = "1",
doi = "10.4046/trd.2013.74.1.1",
language = "English",
volume = "74",
pages = "1--6",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "1",

}

TY - JOUR

T1 - Recent advances in idiopathic pulmonary fibrosis

AU - Park, Sanghoon

AU - Lee, Eun Joo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

AB - The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

KW - Clinical trial

KW - Etiology

KW - Idiopathic pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84874475811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874475811&partnerID=8YFLogxK

U2 - 10.4046/trd.2013.74.1.1

DO - 10.4046/trd.2013.74.1.1

M3 - Review article

VL - 74

SP - 1

EP - 6

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 1

ER -